GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED

December 17, 2025

SMC Ranking

★½☆☆☆ (1.5/5)

Issue Highlights

Industry	Health Care
Fresh Issue (Shares)	2,20,00,000
Net Offer to the Public	2,20,00,000
Issue Size (Rs. Cr.)	237-251
Price Band (Rs.)	108-114
Offer Date	22-Dec-25
Close Date	24-Dec-25
Face Value	2
Lot Size	128 Shares

Issue Composition

	In shares
Total Issue for Sale	2,20,00,000
QIB	1,65,00,000
NIB	33,00,000
Retail	22,00,000

Shareholding Pattern (%)

Particulars	Pre-issue	Post -issue
Promoters & promoters group	99.10%	71.45%
QIB	0.90%	21.57%
NIB	0.00%	4.19%
Retail	0.00%	2.79%
Total	100.00%	100.00%

*calculated on the upper price band

Objects of the Issue

The Company Gujarat Kidney IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

1. Proposed acquisition of Parekhs Hospital at Ahmedabad.
2. Part-payment of purchase consideration for the already acquired "Ashwini Medical Centre".
3. Funding of capital expenditure requirements of the Company towards setting up of a new hospital in Vadodara.
4. Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital in Vadodara location.
5. Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by the Company
6. Funding inorganic growth through unidentified acquisitions and General Corporate Purposes.
7. Acquisition of additional shareholding in the subsidiary namely "Harmony Medicare Private Limited" at Bharuch

Book Running Lead Manager

- Nuvama Wealth Management Ltd
- ICICI Securities Ltd.

Name of the registrar

- MUFG Intime India Private Limited

About the company

Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) is a Gujarat-based healthcare provider offering secondary and tertiary care services across multiple locations in the state. The company operates a network of seven multispeciality hospitals and four pharmacies, with an aggregate bed capacity of 490 beds, approved capacity of 455 beds, and operational capacity of 340 beds. Its hospital portfolio includes facilities in Vadodara, Godhra, Bharuch, Borsad, and Anand, including Gujarat Kidney and Superspeciality Hospital, Gujarat Multispeciality Hospital, Raj Palmland Hospital, Surya Hospital and ICU, Gujarat Surgical Hospital, and Ashwini Medical Centre. GKASSL provides a broad range of medical services spanning general medicine and surgery, minimally invasive procedures, orthopaedics and trauma care, joint replacements, obstetrics and gynaecology, cardiology (non-interventional), diabetology, respiratory care, and anaesthesiology. As of June 30, 2025, the company employed 89 doctors, supported by 332 nurses and 338 other staff.

Strengths

Leadership in renal sciences with established sub-superspecialties in urology: GKSSL has built a strong reputation and deep clinical expertise in renal sciences, positioning it well to benefit from India's growing demand for high-quality tertiary healthcare. In its formative years, Gujarat Kidney Hospital successfully established six urology sub-specialties. Over time, the company has expanded into complex surgical procedures across gynaecology, orthopaedics, joint replacement and related disciplines, while also broadening its core capabilities to include cardiology and associated treatments.

Asset-light operating model with regional focus: GKSSL follows an asset-light strategy, operating hospitals in Godhra and Vadodara on leased premises and expanding through majority-stake acquisitions, thereby minimizing upfront investments in land, buildings and equipment. The proposed acquisition of Parekhs Hospitals, partly funded through IPO proceeds, reflects the continuation of this approach. A concentrated presence in central Gujarat provides strong insight into regional healthcare needs, patient behaviour and medical talent availability, in markets with rising demand for affordable, quality care.

Ability to attract and retain skilled medical professionals: The company's multidisciplinary model, high-volume tertiary care focus, and emphasis on teaching and research enable it to attract and retain experienced doctors, nurses and paramedical staff. Low attrition rates—2.4%–2.99% for full-time doctors, 0%–2.1% for visiting doctors, and negligible nurse attrition—demonstrate workforce stability. Continuous Medical Education programs and long-term professional engagement further support talent retention.

Consistent operational and financial performance: GKSSL has demonstrated a track record of scalable growth while managing concentration risk through a diversified revenue mix. Expansion decisions prioritize hospitals at break-even or near profitability and strong return on capital, with a focus on densely populated catchments. The network has maintained an average bed occupancy of ~54%, with average bed-occupancy revenue of approximately ₹102 crore.

Strategies

Pursue strategic inorganic growth: GKSSL selectively evaluates value-accretive inorganic opportunities aligned with its growth strategy. The company targets micro-markets offering infrastructure advantages, technological upgrades and geographic expansion. Acquisitions such as a 51% stake in Harmony Medicare Private Limited (October 2025) underscore its focus on central Gujarat and operational synergies.

Enhance operational efficiencies: Improving network-wide efficiency remains a key priority through integration of acquisitions and disciplined organic growth. Planned investments in advanced medical technologies, including a Stryker orthopaedic robot, and an increased focus on high-margin tertiary specialties are expected to improve case mix and revenue per occupied bed. Centralization of procurement and partnerships with smaller nursing homes aim to reduce costs and operational redundancies.

Recruit, train and retain healthcare talent: Skilled healthcare professionals are central to GKSSL's strategy. Continuous training, skill enhancement and exposure to advanced procedures are emphasized, supported by tie-ups with medical and nursing colleges to ensure a steady talent pipeline.

Strengthen existing hospitals and add new capabilities: The company plans to deepen specialty offerings and introduce new super-specialties aligned with local demand. Focus areas include urology, nephrology, interventional cardiology and oncology, alongside advanced capabilities such as renal transplant units, interventional urology and 3D imaging across key hospitals.

Infrastructure, equipment and sourcing: GKSSL equips its hospitals with advanced diagnostic and treatment technologies to ensure accurate diagnoses and effective care. While procurement is currently decentralized at the hospital level, vendor selection follows strict quality, pricing and due-diligence protocols, with oversight from hospital leadership.

Risk Factors:

- Given its relatively limited operating history, GKSSL may face challenges in competing effectively with established healthcare providers, and its future operating performance may not be indicative of, or comparable to, its historical results.
- A significant portion of the company's revenues is derived from Gujarat Kidney Hospital in Vadodara. Any operational disruptions, decline in patient volumes, or adverse developments at this facility could materially impact the company's overall financial performance.
- The company's operations are highly dependent on the availability and retention of qualified healthcare professionals, including doctors and nurses. Any inability to

attract, retain or replace such personnel may adversely affect service quality, operational continuity and financial results.

- The healthcare industry is subject to extensive regulatory oversight. Any changes in applicable laws and regulations, delays in compliance, or instances of non-compliance could result in penalties, operational restrictions and adverse impacts on the company's business, financial condition and results of operations.

Peer Comparison

Co_Name	Total Income	PAT	EPS	P/E	P/BV	BV	FV	Price	Mcap
Yatharth Hospit.	988.13	152.49	15.83	43.94	3.97	175.26	10	695.50	6701.45
KMC Speciality	263.74	30.41	1.86	40.43	6.73	11.17	1	75.20	1226.51
GPT Healthcare	429.63	43.42	5.08	25.42	5.35	24.15	10	141.10	1157.79
Gujarat Kidney And Super Speciality Limited	40.24	9.50	1.20	94.62	3.17	35.94	2.00	114.00	898.81

***Peer companies financials are TTM based**
***** Gujarat Kidney and Super Speciality Limited Financials Are Based On FY25**

Valuation:

Considering the P/E valuation, on the upper end of the price band of Rs.114, the stock is priced at pre issue P/E of 68.22x on FY25 EPS of Rs.1.67. Post issue, the stock is priced at a P/E of 94.62x on its EPS of Rs. 1.20. Looking at the P/B ratio at Rs. 114 pre issue, book value of Rs. 5.72 of P/Bvx 19.92x. Post issue, book value of Rs.35.94 of P/Bvx 3.17x.

Considering the P/E valuation, on the lower end of the price band of Rs.108, the stock is priced at pre issue P/E of 64.63x on FY25 EPS of Rs. 1.67. Post issue, the stock is priced at a P/E of 89.64x on its EPS of Rs.1.20. Looking at the P/B ratio at Rs. 108 pre issue, book value of Rs. 5.72 of P/Bvx 18.87x. Post issue, book value of Rs.35.94 of P/Bvx 3.01x.

Industry Outlook:

India's healthcare industry is shaped by a strong preference for private providers, driven by perceptions of superior quality, infrastructure, and service excellence, despite higher costs and significant out-of-pocket spending, particularly in rural areas where public alternatives remain limited. At the same time, India has emerged as a global medical tourism hub, supported by well-trained private-sector professionals offering globally competitive pricing. Public healthcare, though mandated to serve a vast and diverse population, continues to face capacity and service challenges, even as government commitment has strengthened through rising expenditure—from 1.28% of GDP in 2018–19 to about 1.9% in 2023–24, with a target of 2.5% by 2025—and higher budgetary allocations for infrastructure and access. Initiatives such as Ayushman Bharat–PMJAY, including the expansion of health and wellness centres and empanelment of both public and private hospitals, aim to reduce out-of-pocket expenses and improve coverage. Structurally, the sector is dominated by private players, which account for about 63% of hospitals and 62% of beds, while demand is being amplified by demographic shifts, including population growth, ageing, and a rising working-age cohort. The growing burden of non-communicable diseases—responsible for around 60% of deaths in India—along with lifestyle changes, has increased the need for secondary and tertiary care. Although health insurance penetration remains low, it is steadily improving due to rising incomes,

healthcare inflation, and government schemes, collectively supporting sustained growth in India's hospital and healthcare services industry.

Outlook

GKSSL is well positioned to benefit from rising demand for tertiary healthcare, supported by its leadership in renal sciences, asset-light expansion model and strong clinical talent base. Strategic acquisitions, operational efficiencies and specialty expansion are expected to drive growth and improve profitability. However, dependence on key hospitals, regulatory intensity and talent availability remain risks that could influence execution and near-term performance.

An Indicative timetable in respect of the Issue is set out below:

EVENT	INDICATIVE DATE (On or about)
IPO Open Date	Mon, Dec 22, 2025
IPO Close Date	Wed, Dec 24, 2025
Tentative Allotment	Fri, Dec 26, 2025
Initiation of Refunds	Mon, Dec 29, 2025
Credit of Shares to Demat	Mon, Dec 29, 2025
Tentative Listing Date	Tue, Dec 30, 2025

Annexure

Consolidated Financials

Profit & Loss

Rs. in Cr.

Particulars	Period ended 30-Jun-25 (3 Months)	Period ended 31-Mar-25 (12 Months)	Period ended 31-Mar-24 (12 Months)
Revenue from operations	15.26	40.24	4.77
Total expenditure	6.63	23.70	2.82
Operating Profit	**8.63**	**16.55**	**1.95**
OPM%	56.52	41.12	40.86
Other Income	0.01	0.15	0.70
Total Net Income	**8.63**	**16.70**	**2.65**
Interest	0.18	0.65	0.07
PBDT	**8.45**	**16.06**	**2.59**
Depreciation	0.96	3.29	0.32
PBT	**7.49**	**12.77**	**2.27**
Tax	2.09	3.27	0.55
Profit & Loss	5.40	9.50	1.71

Balance sheet is on next page

Balance Sheet

Rs. in Cr.

Particulars	As on 30-Jun-25	As on 31-Mar-25	As on 31-Mar-24
Non-current assets			
Property Plant & Equipment	19.05	19.77	9.74
Right of Use Assets	3.93	4.11	3.90
Goodwill	7.13	7.13	0.00
Financial assets			
Other financial assets	1.73	1.73	0.06
Deferred tax assets, net	0.73	0.68	0.03
Other non-current assets	0.09	0.09	0.07
Total non-current assets	32.66	33.51	13.80
Current asset			
Financial Assets			
Inventories	0.63	0.68	0.27
Financial assets	0.00	0.00	0.00
Trade receivables	21.39	15.16	4.20
Cash and cash equivalents	2.64	2.60	0.97
Bank balances	0.31	0.21	0.20
Other financial assets	0.02	0.01	0.00
Other Current Assets	3.95	3.19	1.08
Total current assets	**28.93**	**21.84**	**6.73**
Total Assets	**61.59**	**55.34**	**20.53**
Non-current liabilities			
Financial liabilities			
Borrowings	2.25	2.14	1.53
Lease liabilities	3.73	3.88	3.70
Other financial liabilities	0.05	0.05	0.00
Provisions	0.52	0.45	0.26
Total Non- Current liabilities	**6.56**	**6.53**	**5.48**
Current liabilities			
Financial Liabilities			
Borrowings	1.77	1.74	0.41
Lease liabilities	0.56	0.54	0.22
Trade Payables			
- Total outstanding dues of MSME	0.00	0.00	0.00
- Total outstanding dues of creditors other than MSME	2.77	3.25	2.19
Other financial liabilities	12.89	13.30	0.21
Other current liabilities	1.31	1.28	0.81
Provisions - current	0.04	0.04	0.02
Current Tax Liabilities, net	3.27	1.54	0.36
Total - Current Liabilities	**22.60**	**21.69**	**4.24**
Total Liabilities	**29.17**	**28.22**	**9.72**
Equity share capital	11.37	11.37	0.20
Other equity	19.42	14.57	10.60
Non controlling interests	1.64	1.19	0.00
Total Equity	**32.43**	**27.13**	**10.80**

E-mail: researchfeedback@smcindiaonline.com

Corporate Office:
11/6B, Shanti Chamber,
Pusa Road, New Delhi - 110005
Tel: +91-11-30111000
www.smcindiaonline.com

Mumbai Office:
Lotus Corporate Park , A Wing 401 / 402 ,
4th Floor ,Graham Firth Steel Compound,
Off Western Express Highway, Jay Coach Signal,
Goreagon (East) Mumbai - 400063
Tel: 91-22-67341600, Fax: 91-22-28805606

Kolkata Office:
18, Rabindra Sarani,
Poddar Court,Gate No.- 4, 5th Floor, Kolkata-700001
Tel: 91-33-39847000, Fax: 91-33-39847004

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The securities quoted are for illustration only and are not recommendatory. SMC is a SEBI registered Research Analyst having registration number INH100001849. CIN : L74899DL1994PLC063609.

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. SMC is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, MSEI (Metropolitan Stock Exchange of India Ltd) and M/s SMC Comtrade Ltd is a registered member of National Commodity and Derivative Exchange Limited and Multi Commodity Exchanges of India and other commodity exchanges in India. SMC is also registered as a Depository Participant with CDSL and NSDL. SMC's other associates are registered as Merchant Bankers, Portfolio Managers, NBFC with SEBI and Reserve Bank of India. It also has registration with AMFI as a Mutual Fund Distributor.

SMC is a SEBI registered Research Analyst having registration number INH100001849. SMC or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities market. SMC or its associates or its Research Analyst or his relatives do not hold any financial interest in the subject company interest at the time of publication of this Report. SMC or its associates or its Research Analyst or his relatives do not hold any actual/beneficial ownership of more than 1% (one percent) in the subject company, at the end of the month immediately preceding the date of publication of this Report. SMC or its associates its Research Analyst or his relatives does not have any material conflict of interest at the time of publication of this Report.

SMC or its associates/analyst has not received any compensation from the subject company covered by the Research Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the subject company covered by analyst or third party in connection with the present Research Report. The Research Analyst has not served as an officer, director or employee of the subject company covered by him/her and SMC has not been engaged in the market making activity for the subject company covered by the Research Analyst in this report.

The views expressed by the Research Analyst in this Report are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty expressly or impliedly to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the subject company.

Disclaimer: This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s)in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance if this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies); or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.